

FOR IMMEDIATE RELEASE

BAXTER LAUNCHES DIGITAL IMAGE CAPTURE CAPABILITY FOR PANOPTIC PLUS OPHTHALMOSCOPE

- Helps support faster diagnosis, enabling earlier treatment of eye conditions
- Enables a more digitally connected primary care exam
- Facilitates collaboration and education among primary care clinicians, specialists, patients and family members

DEERFIELD, III., OCTOBER 16, 2023 – Baxter International Inc. (NYSE:BAX), a leader in patient monitoring, physical assessment and vision screening products, announced the launch of digital image capture capability for eye exams using its existing **Welch Allyn PanOptic Plus** Ophthalmoscope. The **iExaminer Pro** System adds a key technology to routine eye exams, designed to help advance healthcare professionals' ability to examine and diagnose the eye health of patients.

"Healthcare settings have never been more demanding, and clinicians need their tools to offer improved efficiency and accuracy that ultimately allows earlier care for patients," said Jim O'Connell, president, Front Line Care, Baxter. "The **iExaminer Pro** System uses the latest tech, allowing providers to spend more time focusing on the thing that matters most – their patients."

The **PanOptic Plus** Ophthalmoscope with **iExaminer Pro** System adds the ability to connect a smart device to capture images for further examination and enables clinicians to move quickly from an optical exam to adding digital image capture. When used with the **iExaminer Pro** App, clinicians can securely save and share eye images for tracking and trending and initiate more informed consultations with specialists.

"Examining the structure of the eyes is a critical part of assessing patient health," said Julie Jakubowski, M.D., F.A.C.P., head of medical affairs, Front Line Care, Baxter. "The **PanOptic Plus** Ophthalmoscope with **iExaminer Pro** System helps to enable healthcare providers to catch issues early on in a primary care setting, easily collaborate with specialists, and facilitates patients getting the diagnosis, care and treatment they need in a timely manner."

The **iExaminer Pro** System has been in use with Baxter's **Welch Allyn MacroView Plus** Otoscope since 2021. The addition of digital image capture capability for eye exams represents the



company's continued commitment to using connected devices to help improve patient outcomes via routine physical exams.

The **PanOptic Plus** and **MacroView Plus** tools offer clinicians bigger views compared to standard ophthalmoscopes and otoscopes, plus additional key features such as long-lasting LED lamps and **DuraShock** technology for durability.

The new offering is now available in the U.S. and will be showcased at the upcoming American Academy of Pediatrics National Conference & Exhibition (Oct. 20-24) and American Academy of Family Physicians Family Medicine Experience conference (Oct. 26-29). Find more information and the full range of <u>product capabilities here</u>.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit <u>www.baxter.com</u> and follow us on <u>Twitter</u>, <u>LinkedIn</u> and <u>Facebook</u>.

This release includes forward-looking statements concerning potential benefits associated with the **Welch Allyn PanOptic Plus** Ophthalmoscope with **iExaminer Pro** System. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter, DuraShock, iExaminer Pro, MacroView Plus, PanOptic Plus and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries.

Media Contact Natalie Matthews, (224) 515-0219



media@baxter.com

Investor Contact Clare Trachtman, (224) 948-3020

###